"The story does not mention costs of either drug, other than to describe the costs of ellaOne as ""three times the price of Plan B."" The story adequately quantifies the benefits of ellaOne by presenting both the number of pregnancies and the pregnancy rate in both groups. The story doesn’t mention any potential harms of the drug, other than unwanted pregnancy. In the study 19% of women experienced headaches and one dizziness. Common side effects of the drug also include stomach pain and nausea, cramps, and vaginal bleeding. None of these were mentioned in the story. The story adequately describes the design of the current study. The story does not engage in disease-mongering. The story quotes two independent health officials who provide very valuable perspectives on the new findings. The story compares the new drug to the existing option, Levonorgestrel. The story clearly states that ellaOne is only available by prescription in Europe, whereas Levonorgestrel is available in many countries worldwide, including the US. The story accurately represents the novelty of ellaOne compared to Levonorgestrel. Because the story quotes independent researchers and health officials, the reader can assume the story does not rely on a press release as the sole source of information."
New morning-after pill works for up to 5 days